MediWound Ltd(MDWD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.6 | Insider Own | 25.52% | Shs Outstand | 12.9M | Perf Week | 13.79% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | -0.3% | Insider Trans | 0.12% | Shs Float | 9.6M | Perf Month | 0.65% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.71 | Inst Own | 53.87% | Short Float | 18.19% | Perf Quarter | -1.84% |
| Income | -0.02B | P/S | 15.09 | EPS this Y | -4.37% | Inst Trans | 0.45% | Short Ratio | 18.93 | Perf Half Y | -16% |
| Sales | 0.01B | P/B | 5.02 | EPS next 5Y | 16.86% | ROA | -29.06% | Short Interest | 1.75M | Perf YTD | -24.92% |
| Book/sh | 2.76 | P/C | 5.06 | EPS past 3/5Y | 18.87% 2.36% | ROE | -72.37% | 52W High | -29.64% ($19.70) | Perf Year | -23.3% |
| Cash/sh | 2.74 | P/FCF | - | Sales past 3/5Y | -13.82% -4.87% | ROIC | -45.6% | 52W Low | 17.46% ($11.80) | Perf 3Y | 78.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.18% | Gross Margin | 15.46% | Volatility(W/M) | 4.53% 4.06% | Perf 5Y | -43.75% |
| Dividend TTM | - | EV/Sales | 12.91 | Sales Y/Y TTM | -40.26% | Oper. Margin | -271.59% | ATR (14) | 0.53 | Perf 10Y | -68.32% |
| Dividend Ex-Date | - | Quick Ratio | 2.09 | EPS Q/Q | 53.32% | Profit Margin | -170.1% | RSI (14) | 62.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.32 | Sales Q/Q | -45.83% | SMA20 | 10.06% ($12.59) | Beta | 0.07 | Target Price | $30.67 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/11/12 | SMA50 | 6.18% ($13.05) | Rel Volume | 1.67 | Prev Close | $13.56 |
| Employees | 121 | LT Debt/Eq | 0.24 | EPS/Sales Surpr. | -1.09% 19.44% | SMA200 | -9.14% ($15.25) | Avg Volume(3M) | 0.09M | Price | $13.86 |
| IPO | 2014/3/20 | Option/Short | Yes/Yes | Trades | 1826 | Volume | 154,410 | Change | 2.21% |
🩹 MediWound (MDWD) is a global biotech company developing enzyme-based, non-surgical tissue regeneration therapies. Its flagship commercial product is NexoBrid, an FDA- and EMA-approved enzymatic burn eschar removal agent, and it is also developing EscharEx, a chronic wound treatment, in late-stage clinical trials. By leveraging enzyme technology that replaces surgical excision, the company is driving a shift toward a new standard of care in the wound and burn treatment market.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded more than usual. That is 167% of its average volume.
Next earnings report: November 12
13 days to go.
MDWD has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -4.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,509. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -43.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #312 of 594 in the industry
Based on market cap of $179M.
SION#309 Sionna Therapeutics Inc $181M PER - 
ADAG#310 Adagene Inc ADR $180M PER - 
UPB#311 Upstream Bio Inc $179M PER - MDWD#312 MediWound Ltd $179M PER - 
IVVD#313 Invivyd Inc $177M PER - 
FAQ
What kind of company is MDWD?
MDWD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MDWD?
The market cap of MDWD is approximately $179M, ranking 4,113 within its sector.
What is the 52-week high and low for MDWD?
MDWD has recorded a 52-week high of $19.70 and a low of $11.80.
